title: Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems.
abstract: BACKGROUND
  Cervical cancer is the second-most-common cause of malignancies in women worldwide, and the oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors. In this study, we have designed a therapeutic vaccine based on chitosan nanodelivery systems to deliver HPV-16 E7 DNA vaccine, considered as a tumor specific antigen for immunotherapy of HPV-associated cervical cancer. We have developed a Nano-chitosan (NCS) as a carrier system for intramuscular administration using a recombinant DNA vaccine expressing HPV-16 E7 (NCS-DNA E7 vaccine). NCS were characterized in vitro for their gene transfection ability.
  
  
  RESULTS
  The transfection of CS-pEGFP NPs was efficient in CHO cells and the expression of green fluorescent proteins was well observed. In addition, NCS-DNA E7 vaccine induced the strongest E7-specific CD8+ T cell and interferon γ responses in C57BL/6 mice. Mice vaccinated with NCS-DNA E7 vaccine were able to generate potent protective and therapeutic antitumor effects against challenge with E7-expressing tumor cell line, TC-1.
  
  
  CONCLUSIONS
  The strong therapeutic effect induced by the Chitosan-based nanodelivery suggest that nanoparticles may be an efficient carrier to improve the immunogenicity of DNA vaccination upon intramuscular administration and the platform could be further exploited as a potential cancer vaccine candidate in humans.
authors: Alireza
authors: A
authors: Tahamtan
authors: Amir
authors: A
authors: Ghaemi
authors: Ali
authors: A
authors: Gorji
authors: Hamid R
authors: HR
authors: Kalhor
authors: Azadeh
authors: A
authors: Sajadian
authors: Alijan
authors: A
authors: Tabarraei
authors: Abdolvahab
authors: A
authors: Moradi
authors: Fatemeh
authors: F
authors: Atyabi
authors: Mishar
authors: M
authors: Kelishadi
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D048271:Chitosan / Q000494:pharmacology*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D051379:Mice; D050725:Papillomavirus E7 Proteins / Q000276:immunology / Q000494:pharmacology; D053918:Papillomavirus Vaccines / Q000276:immunology / Q000494:pharmacology; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology / Q000494:pharmacology
chemical_list: D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16; D048271:Chitosan